The FDA has accepted applications for three new indications for bimekizumab-bkzx, a humanized interleukin (IL) 17A and IL-17F antagonist: psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.
The ACR will lead five other specialty societies on a resolution supporting pediatric specialty care and will co-lead resolutions addressing Medicare Advantage Part B drug coverage, white bagging mandates, state prescription drug affordability boards and impacts of alternative funding programs on access to care.
Rheumatology fellow Audrey Liu, MD, describes the excitement and empowerment of seeing first-hand the real-world impact of advocating for policies that support providers and patients.
On May 6–7, nearly 100 rheumatologists and rheumatology professionals converged in Washington, D.C., for the ACR’s annual Advocacy Leadership Conference and 137 meetings on Capitol Hill. You can help extend the efforts of these advocates and amplify their impact by contacting your lawmakers via the Legislative Action Center.
Don’t reinvent the wheel. The ACR Committee on Rheumatologic Care offers members an updated slate of template letters to help appeal insurance denials for common off-label rheumatology treatments.
Novice writers often wait months, sometimes even years, before their first piece is published. However, Usman T. Malik, MBBS, shares a different experience. His letter to the editor of Bachon ka Pakistan, a Pakistani children’s publication, was published shortly after being submitted. He was just 7 years old. Dr. Malik is now an assistant professor…
Carola Vinuesa, MD, PhD, Honored with Lupus Insight Prize In June 2023 at the 23rd Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS), Carola Vinuesa, MD, PhD, a Royal Society Wolfson fellow and assistant research director at the Francis Crick Institute, London, was awarded the Lupus Research Alliance’s Lupus Insight Prize. The $100,000…
A handful of articles on artificial intelligence (AI) have graced the pages of this publication in the past six years, including one by Bharat Kumar, MD, in November 2022. Dr. Kumar highlighted the exciting potential of AI in rheumatology, including machine learning (ML) algorithms for the prediction of response to methotrexate and a predictive model…